Comparison of two immunotoxins against DLL3 receptor; as an inhibitor for small cell lung cancer [PDF]
Frontiers in Molecular BiosciencesDespite the efforts of researchers to develop new treatments for small cell lung cancer (SCLC), achieving effective treatment has not yet happened. Targeted therapy utilizing delta-like ligand 3 (DLL3), which is highly expressed in SCLC patients, holds ...
Mohammad Hossein Ataee +4 more
doaj +2 more sources
Comparative Efficacy of Ribosome-Inactivating Protein-Containing Immunotoxins in 2D and 3D Models of Sarcoma [PDF]
ToxinsSarcomas are very complex and clinically challenging mesenchymal tumors. Although the standard therapeutic approach has improved the 5-year survival rate, many patients experience local relapses and/or distant metastases.
Giulia Calafato +3 more
doaj +2 more sources
Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes [PDF]
Toxins, 2023 The production of therapeutic recombinant toxins requires careful host cell selection. Bacteria, yeast, and mammalian cells are common choices, but no universal solution exists.
Luana di Leandro +3 more
doaj +2 more sources
Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH [PDF]
Journal of Translational Medicine, 2023 Background Immunotoxins are antibody-toxin conjugates that bind to surface antigens and exert effective cytotoxic activity after internalization into tumor cells.
Xiaoyu Liu +15 more
doaj +2 more sources
A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTEFAP5/CD3, CAR-T cells, and immunotoxins in hepatocellular carcinoma [PDF]
Frontiers in ImmunologyBackgroundAlthough the treatment landscape for advanced hepatocellular carcinoma (HCC) has seen significant advancements in the past decade with the introduction of immune checkpoint inhibitors and antiangiogenic drugs, progress has fallen short of ...
Shuang Dong +17 more
doaj +2 more sources
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. [PDF]
, 2011 BackgroundTumor microenvironments present significant barriers to penetration by antibodies and immunoconjugates. Tumor microenvironments, however, are difficult to study in vitro.
Broaddus, V Courtney +8 more
core +21 more sources
Preclinical Studies of Granulysin-Based Anti-MUC1-Tn Immunotoxins as a New Antitumoral Treatment
Biomedicines, 2022 Two granulysin (GRNLY) based immunotoxins were generated, one containing the scFv of the SM3 mAb (SM3GRNLY) and the other the scFv of the AR20.5 mAb (AR20.5GRNLY). These mAb recognize different amino acid sequences of aberrantly O-glycosylated MUC1, also
Patricia Guerrero-Ochoa +11 more
doaj +1 more source
Immunotoxins: From Design to Clinical Application
Biomolecules, 2021 The Special Issue of Biomolecules entitled “Immunotoxins, From Design to Clinical Application” contains seven reviews related to immunotoxins [...]
Robert J. Kreitman, Ira Pastan
doaj +1 more source
Research in Pharmaceutical Sciences, 2022 Background and purpose: The lack of a new effective treatment for small cell lung cancer (SCLC) is an unresolved problem. Due to the new identification of delta-like ligand 3 (DLL3) and its high expression in SCLC patients, the use of DLL3 in target ...
Mohammad Hossein Ataee +5 more
doaj +1 more source
Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect
Toxins, 2021 Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. Therefore, fighting against such cancer is reasonable. Chemotherapy drugs are sometimes inefficient and often accompanied by undesirable side effects for patients.
Mohammad Heiat +3 more
doaj +1 more source